March 20 (Reuters) - Johnson & Johnson JNJ.N:
U.S. FDA APPROVES TREMFYA® (GUSELKUMAB), THE FIRST AND ONLY IL-23 INHIBITOR OFFERING BOTH SUBCUTANEOUS AND INTRAVENOUS INDUCTION OPTIONS, FOR ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
Source text: ID:nPn3rpDJva
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments